Stepwise progress

ImmusanT’s journey towards clinical POC takes a leap with $40M series C

After six years and four Phase I trials ImmusanT Inc. has finally nailed down the optimal dose regimen for celiac disease vaccine Nexvax2 and is ready to take the leap into Phase IIb testing with its $40 million series C

Read the full 401 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE